USA flag logo/image

An Official Website of the United States Government

Novel Reagents For The Detection Of Low Abundance Cancer Specific Glycoforms

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95940
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
CA153822
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
TOPH BIOLOGICALS, INC.
3805 OLD EASTON RD DOYLESTOWN, PA 18902
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Novel Reagents For The Detection Of Low Abundance Cancer Specific Glycoforms
Agency: HHS
Contract: 1R43CA153822-01
Award Amount: $194,005.00
 

Abstract:

DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide and the incidence in the United States is increasing. It has been estimated that the number of cases of HCC will continue to increase by 81% (from a baseline of about 13,000 a year) by the year 2020, primarily due to the hepatitis C (HCV) epidemic. Despite advances in medical technology, the 5-year survival between 1981 and 1998 improved only 3%, likely due to the fact that the majority of patients with HCC are diagnosed at advanced stages leading to an overall 1-year survival of 25% in the United States. Early diagnosis of HCC in patients at risk for liver disease will help improve outcome. N-linked glycosylation changes of specific ser um biomarker proteins occur with the development of liver cancer. The specific aims of this grant are focused on developing high affinity binding lectins (carbohydrate binding proteins) that recognize the glycsoylation changes that occur on serum biomarker s of HCC (Specific Aim 1) and using these recombinant lectins in an ELISA based format on archived patient serum samples to test their sensitivity and specificity for predicting liver disease and HCC (Specific Aim 2). PUBLIC HEALTH RELEVANCE: The in cidence of hepatocellular carcinoma (HCC) is increasing worldwide with a poor prognosis for survival related to the lack of predictive assays for early detection. Sensitive, specific, non-invasive assays that are predictive for diagnosing HCC in patients a t risk for liver disease are urgently needed.

Principal Investigator:

Michael J. Ciocci

Business Contact:

Pippin Douglas
Small Business Information at Submission:

TOPH BIOLOGICALS, INC.
TOPH BIOLOGICALS, INC. 3805 OLD EASTON RD DOYLESTOWN, PA 18902

EIN/Tax ID: 127131209
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No